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The N-glycosylation of immunoglobulin (Ig) G, the major antibody in the circulation of
human adults, is well known for its influence on antibody effector functions and its
alterations with various diseases. In contrast, knowledge on the role of glycans attached
to IgA, which is a key immune defense agent in secretions, is very scarce. In this
study we aimed to characterize the glycosylation of salivary (secretory) IgA, including
the IgA joining chain (JC), and secretory component (SC) and to compare IgA and IgG
glycosylation between human plasma and saliva samples to gain a first insight into oral
cavity-specific antibody glycosylation. Plasma and whole saliva were collected from 19
healthy volunteers within a 2-h time window. IgG and IgA were affinity-purified from the
two biofluids, followed by tryptic digestion and nanoLC-ESI-QTOF-MS(/MS) analysis.
Saliva-derived IgG exhibited a slightly lower galactosylation and sialylation as compared
to plasma-derived IgG. Glycosylation of IgA1, IgA2, and the JC showed substantial
differences between the biofluids, with salivary proteins exhibiting a higher bisection,
and lower galactosylation and sialylation as compared to plasma-derived IgA and JC.
Additionally, all seven N-glycosylation sites, characterized on the SC of secretory IgA
in saliva, carried highly fucosylated and fully galactosylated diantennary N-glycans. This
study lays the basis for future research into the functional role of salivary Ig glycosylation
as well as its biomarker potential.
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INTRODUCTION
Using saliva for diagnostic purposes has gained increasing popularity due to its various advantages
over plasma or serum. First, saliva can be easily and painlessly collected from donors without the
need for specialized equipment or training. Second, next to proteins derived from serum (ca. 27% of
total salivary proteins), saliva also contains locally produced proteins which might reflect diseases
that affect the oral cavity, such as Sjögren’s syndrome, or oral cancer (1–3). Saliva assays are already
available on the market, e.g., for the detection of antibodies against HIV (1). Moreover, numerous
potential salivary protein-, DNA-, RNA-, and small-molecule-based biomarkers for various diseases
have been proposed, as recently reviewed (4). Furthermore, two studies using global lectin-based
profiling of glycans in saliva revealed associations with breast cancer and Sjögren’s syndrome (5, 6).
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Glycosylation is a prevalent posttranslational modification
which heavily influences the structure and function of proteins,
as is well known for plasma-derived immunoglobulin (Ig) G. The
glycosylation of the fragment crystallizable (Fc) portion of IgG
has been shown to influence binding to Fcγ receptors (FcγRs)
and complement factors (7). Moreover, plasma IgG glycosylation
has been associated with various diseases and could, therefore,
be exploited for diagnostic and therapeutic approaches in the
future (8–10). In contrast, for other Igs, such as IgA, less is known
about the relationship between their glycosylation and effector
functions. Although IgA N-glycosylation was shown to influence
the IgA transport from circulation to mucosal tissue (11) and
the O-glycosylation of IgA1 is considered a major factor in the
pathogenesis of IgA nephropathy (12), the absence of the Fc N-
glycosylation of IgA1 had no effect on FcαR binding (13). Site-
specific investigation of antibody glycosylation in human samples
other than plasma has been limited to cerebrospinal fluid and
synovial fluid for IgG (14, 15) and colostrum for IgA (16, 17).
The glycosylation of saliva-derived IgG and IgA has only been
crudely examined using lectin binding assays, and without a
direct comparison to blood (18, 19).
The lack of knowledge about salivary antibody glycosylation
is mainly due to the fact that the antibody concentrations are
much lower than in plasma, posing a major challenge for their
in-depth characterization. Plasma contains approximately 12.5
mg/mL IgG and 2.2 mg/mL IgA, while the concentrations for
unstimulated whole saliva are estimated at approximately 0.014
and 0.19 mg/mL for IgG and IgA, respectively (20, 21). Salivary
IgG is thought to mainly be derived from circulation, while a
minority (<20%) is produced by local plasma cells in gingival
lesions or salivary glands (20, 22). In contrast, more than 95%
of salivary IgA is produced locally by plasma cells in various
glands, where it can form a dimeric complex via the associated
joining chain (JC) (23). Secretion of dimeric IgA across the
epithelial layer is enabled by the polymeric Ig receptor (pIgR),
of which a part remains bound to the IgA and is known as the
secretory component (SC). As a consequence, secretory (S)IgA
as a complex of dimeric IgA covalently linked to the JC and
SC (Figure 1), contributes to more than 80% of the salivary
IgA pool, as opposed to plasma IgA which is predominantly
(∼90%) monomeric (20, 26). In addition, the ratio between
IgA1 and IgA2 is dependent on the source of IgA: while saliva
contains approximately 35% IgA2, around 20% IgA2 is found
in serum (20, 26). In contrast to IgG, which only contains one
glycosylation site, or two in case of some IgG3 variants (27),
the constant domains of IgA1 and IgA2 contain two up to five
potential N-glycosylation sites, respectively, and IgA1 carries
up to six O-glycans in the hinge region (24, 28) (Figure 1). In
addition, the JC has one and the SC seven N-glycosylation sites
(Figure 1). This further complicates detailed (S)IgA glycosylation
analysis. However, in recent years great progress has been made
with respect to both measurement sensitivity and data analysis
tools in the field of glycoproteomics, facilitating site-specific
glycosylation analysis of minute amounts of Igs (29–32).
Here, we developed a method for the analysis of IgG and
(S)IgA glycosylation in whole saliva using bead-based affinity
chromatography purification, followed by tryptic digestion
FIGURE 1 | Schematic representation of IgG1, IgA1, and SIgA2 and
their glycosylation sites. IgA2 is shown in its dimeric form, in a complex with a
joining chain (JC; red) and a secretory component (SC; blue). The JC and SC
are covalently linked to IgA by disulfide bonds (not shown). Each Ig monomer
is composed of two heavy chains (dark gray) and two light chains (light gray),
again connected by disulfide bonds. The chains are further subdivided as
constant (C) and variable (V) domains. N-glycosylation sites on IgG are
indicated by their amino acid number according to the nomenclature used by
conventional literature, e.g., (24), while IgA, the JC and SC have UniProt
numbering (25). N92 on IgA2 was previously reported to be glycosylated,
however, N92 on the IgA2 allotype found in our samples [A2m(1)] was not
incorporated in a N-glycosylation consensus sequence and was found to be
non-glycosylated.
and analysis with nano liquid chromatography (nanoLC)-
electrospray ionization (ESI)-quadrupole time-of-flight (QTOF)-
mass spectrometry (MS). The method can be used in a 96-well
plate format and was applied to characterize and compare the
glycosylation of both IgG and (S)IgA in saliva and plasma of 19
healthy individuals. To the best of our knowledge we are the first
to report site-specific glycoprofiling of antibodies in saliva.
MATERIALS AND METHODS
Collection of Biofluids and Preprocessing
Nineteen healthy donors (18 Caucasians and 1 of South
Asian ancestry) were recruited to donate blood and saliva.
The study population included 13 females and 6 males, with
an average age of 28.4 years (range: 20–42). All donors gave
informed consent, and the study was approved by the Medical
Ethics Commission of the Leiden University Medical Center
(P16.189). Both biofluids were collected between 10:30 a.m. and
12:30 p.m. on the same day. Donors were instructed to rinse
their mouth with water an hour prior to collection of saliva
and abstain from food and beverages until sample collection was
finished. Saliva was collected by unstimulated drooling into a 5-
mL Eppendorf tube for approximately 10min, and immediately
frozen at −20◦C. Subsequently, 10mL of venous blood was
collected in an EDTA vial. The blood was centrifuged at 3184× g
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for 5min and the clear upper fraction, consisting of plasma, was
collected and frozen at−20◦C.
Saliva samples underwent a preprocessing step to reduce
viscosity: After thawing, the samples were centrifuged at 3184× g
at 4◦C for 30min. Four hundred µL of supernatant was collected
from each sample and dispersed over four aliquots of 100µL (for
IgG and IgA purification each in duplicate), which were added to
a 96-well filter plate with a 10µmpore frit (Orochem, Naperville,
IL). The samples were centrifuged at 200 × g for 1min, and
flow-throughs were used for IgG and IgA affinity purification
immediately after.
Purification and Digestion of
Immunoglobulins From Donor Plasma and
Saliva
IgG and IgA were each purified in duplicate on separate
plates using affinity bead chromatography, based on a protocol
described previously (33). For IgG purification, 15 µL of Protein
G Sepharose 4 Fast Flow beads (GEHealthcare, Uppsala, Sweden)
were added per well on an Orochem filter plate and washed three
times with phosphate-buffered saline (PBS). For IgA purification,
the same procedure was followed using 2 µL CaptureSelect
IgA Affinity Matrix beads (Thermo Fisher Scientific, Breda, The
Netherlands). For IgG purification, either 100 µL of saliva or 2
µL of plasma was added to each well, while 100 µL of saliva or 5
µL of plasma was used for IgA purification. Sample volumes were
brought to a total of 200 µL by the addition of PBS. The plates
were incubated for 1 h while shaking at 750 rpm with 1.5mm
orbit (Heidolph Titramax 100; Heidolph, Kelheim, Germany) to
accommodate binding.
Using a vacuum manifold, the samples were washed three
times by adding 400 µL PBS, followed by three times 400 µL
of purified water (Purelab Ultra, maintained at 18.2 MΩ ; Veolia
Water Technologies Netherlands B.V., Ede, The Netherlands).
The antibodies were eluted from the beads by adding 100
µL of 100mM formic acid (Sigma-Aldrich, Zwijndrecht, The
Netherlands), incubating for 5min at 750 rpm, and centrifuging
at 100 × g for 2min. Samples were dried for 2 h at 60◦C in a
vacuum centrifuge.
The IgG samples were resolubilized in 20 µL 50mM
ammonium bicarbonate (Sigma-Aldrich) while shaking for 5min
at 750 rpm. Twenty µL of 0.05 µg/µL tosyl phenylalanyl
chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich) in
ice-cold purified water was added per well, and the samples were
incubated at 37◦C overnight.
In contrast to IgG, IgA molecules need to be reduced and
alkylated prior to digestion to obtain peptides covering all
glycosylation sites. IgA samples were resolubilized in 30 µL
30mM ammonium bicarbonate, 12.5% acetonitrile (Biosolve,
Valkenswaard, the Netherlands) while shaking for 5min at
750 rpm. Subsequently, 5 µL of 35mM dithiothreitol (Sigma-
Aldrich) was added, followed by 5min incubation at room
temperature on a shaker (750 rpm) and 30min incubation at
60◦C in an oven. After cooling to room temperature, 5 µL
of 125mM iodoacetamide (Sigma-Aldrich) was added and the
samples were incubated in the dark while shaking for 30min.
Two µL of 100mM dithiothreitol was added to quench the
iodoacetamide. Finally, 8µL of 0.08µg/µL TPCK-treated trypsin
in ice-cold purified water was added per well, and the samples
were incubated at 37◦C overnight. Before LC-MS analysis,
IgA and IgG samples derived from plasma were diluted twice
and 20-times, respectively, with purified water, whereas saliva-
derived samples were not diluted. Assuming no losses and prior
concentrations of 12.5 mg/mL plasma IgG, 0.014 mg/mL saliva
IgG, 2.2 mg/mL plasma IgA and 0.19 mg/mL saliva IgG (20, 21),
the concentrations of the final digests were 0.031, 0.035, 0.110,
and 0.380 mg/mL for plasma IgG, saliva IgG, plasma IgA, and
saliva IgA, respectively.
Digestion and N-Glycan Release of IgA
Samples for MS/MS Analysis
For the fragmentation analysis by MS/MS of the IgA
glycopeptides, a separate purification and tryptic digestion of IgA
was done in triplicate on two saliva samples from two donors
from the study described above, a pooled-plasma standard from
a minimum of 20 human donors (VisuCon-F Frozen Normal
Control Plasma; Affinity Biologicals, Ancaster, Canada), 10 µg
of a human plasma-derived IgA standard (Lee Biosolutions,
Maryland Heights, MO), and a human colostrum-derived SIgA
standard (Athens Research and Technology, Athens, GA). The
procedure was similar to what is described above, except that 1
µg trypsin per sample was used instead of 0.64 µg. Twenty µL
of trypsin-digested sample was collected and heated to 95◦C to
inactivate the trypsin. After cooling to room temperature, 1µL of
N-glycosidase F (Roche Diagnostics, Mannheim, Germany) was
added and the samples were incubated at 37◦C overnight. The
samples obtained from the pooled-plasma standard were diluted
twice and the (S)IgA standard samples thrice with purified water,
whereas the saliva-derived samples were not diluted.
NanoLC-ESI-QTOF-MS(/MS) Analysis
IgG and IgA samples were present on separate plates and
measured on different days. Each pair of plasma and saliva
sample of the same donor was analyzed successively, but the
duplicate pair of the same donor was measured at a later time
point. Blanks consisting of purified water were run after every
20 samples. Two hundred nL of each sample was injected
into an Ultimate 3000 RSLCnano system (Dionex/Thermo
Scientific, Breda, the Netherlands) coupled to a quadrupole-
TOF-MS (MaXis HD; Bruker Daltonics, Bremen, Germany). The
LC system was equipped with an Acclaim PepMap 100 trap
column (particle size 5µm, pore size 100 Å, 100µm × 20mm,
Dionex/Thermo Scientific) and an Acclaim PepMap C18 nano
analytical column (particle size 2µm, pore size 100 Å, 75µm
× 150mm, Dionex/Thermo Scientific). A mixture of solvent
A (0.1% formic acid in purified water) and solvent B (95%
acetonitrile) was applied with a constant flow of 0.7 µL/min
using a linear gradient: t(min) = 0, %B = 3; t = 5, %B = 3;
t = 35, %B = 53; with washing and equilibration starting
at t = 36, %B = 70; t = 38, %B = 70; t = 39, %B = 3;
t = 58, %B = 3. The sample was ionized in positive-ion mode
using a CaptiveSprayer (Bruker Daltonics) electrospray source at
1300V. A nanoBooster (Bruker Daltonics) was used to enrich the
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nitrogen gas with acetonitrile to enhance ionization efficiency.
Mass spectra were acquired with a frequency of 1Hz and the
MS ion detection window was set at mass-to-charge ratio (m/z)
550–1800. Fragmentation spectra were recorded with a detection
window ofm/z 50–2800.
Data Processing
LC-MS(/MS) data were first examined manually using
DataAnalysis (Bruker Daltonics). Glycopeptides were identified
based on their m/z and literature (Supplemental Table S1)
(17, 33–40). In the following, glycosylation site numbering
for IgG is based on conventions commonly used in literature,
e.g., (24), and for IgA1, IgA2, the JC and the SC, UniProt
numbering is used (25) (Figure 1). For each glycopeptide
cluster, here defined as a group of glycopeptides sharing the
same peptide portion, e.g., IgA2 N205, at least one glycopeptide
was characterized by MS/MS fragmentation, elucidating
the glycan composition and the identity of the peptide
(Supplemental Figure S1). In order to provide information on
the peptide sequence of the IgA glycopeptides, a proteomics
analysis (MASCOT Deamon version 2.2.2; Matrix Science,
London, UK) was run on the LC-MS/MS data of the N-
glycosidase F-digested IgA samples, in which the N-glycans
had been released. The following settings were used: database:
SwissProt (2017_09); taxonomy: Homo sapiens; enzyme:
trypsin; fixed modifications: carbamidomethyl (C); variable
modifications: oxidation (M), deamidated (NQ) and Gln:pyro-
Glu (N-term Q); maximal number of missed cleavages: 2;
peptide tolerance MS: 0.05 Da; peptide tolerance MS/MS:
0.07 Da (Supplemental Table S2). The peptides covering
IgA2 N47 and N92 were not recognized by the software, but
could still be manually identified (Supplemental Figure S2).
The proteomics data are available via ProteomeXchange with
identifier PXD011228.
For IgA1/2 N340/N327, two different peptide sequences were
identified in N-glycosidase F-treated samples: the expected
LAGKPTHVNVSVVMAEVDGTCY and the truncated
LAGKPTHVNVSVVMAEVDGTC, lacking the C-terminal
tyrosine, as described before by Bondt et al. (35). Both of these
peptides eluted at two different retention times: a minor peak
(<20%) first, and a higher peak eluting 1min later. The same
pattern could be seen in samples that were not treated with
N-glycosidase F. For data analysis, only the higher, later-eluting
peak was included, since the lower peak was often of too low
signal quality.
LC-MS data were calibrated in DataAnalysis based on a list
of the expected m/z values of either IgG1 N297 or IgA N205
glycopeptides. The data files were then converted to mzXML
format using the MSconvert program from the ProteoWizard
3.0 suite. Alignment of the time axis of the data and extraction
of glycopeptide signal intensities, based on sum spectra, was
done using the in-house developed LacyTools software, with
a list of manually compiled glycopeptides and their retention
times as input (29). For signal extraction, area integration was
performed within an m/z window of ±0.05 Th around each
isotopic peak (with the minimum theoretical % of signal intensity
covered by the sum of the integrated isotopic peaks at 85%)
within an individually specified time window surrounding the
retention time. This resulted in background-corrected signal
areas for each glycopeptide per charge state {[M+2H]2+ to
[M+7H]7+}. Whether an analyte was present in a sample,
was determined based on the signal-to-noise ratio (S/N; > 9),
the isotopic pattern quality score (IPQ; < 0.2) and the mass
accuracy (<10 ppm deviation) of each signal per charge state.
Data of specific glycopeptide clusters were excluded for further
processing when either the total number of analytes detected
was <50% of the maximum number detected for that cluster,
or when the summed absolute intensity of the detected analytes
was <5% of the maximum sum observed for that cluster.
This assessment was performed separately for samples obtained
from saliva or plasma. Subsequently, individual analytes were
subjected to quality control criteria to determine which were
of sufficient quality for relative quantification. Glycopeptides in
specific charge states were included for relative quantification
if their signal showed a S/N > 9, IPQ < 0.2 and an absolute
mass error <10 ppm in at least 25% of either all plasma or
all saliva samples. Finally, all included charge state signals for
the same glycopeptide were summed and absolute abundances
were corrected for the fraction of isotopes integrated. The
glycopeptide signals were normalized on the total signal intensity
per glycopeptide cluster, resulting in the relative quantification of
each glycopeptide.
Based on the N-glycan monosaccharide compositions,
glycoforms were categorized as bisected, high-mannose or
hybrid, and, in addition, the number of fucoses, galactoses,
and sialic acids was determined (Supplemental Table S1).
This was used for the calculation of several glycosylation
features per glycosylation site, based on total-area normalized
data. Fucosylation represents the number of fucoses per
complex-type N-glycan, i.e., sum [(complex-type species with n
fucoses)∗n]/sum(complex-type species). Bisection represents the
fraction of bisected complex-type N-glycans, i.e., the sum of all
structures presumed to carry a β1-4-linked N-acetylglucosamine
(GlcNAc) on the innermost mannose, divided by the sum
of all complex-type glycoforms. Galactosylation was calculated
as the number of galactoses per complex-type N-glycan, i.e.,
sum [(complex-type species with n galactoses)∗n]/sum(complex-
type species). Sialylation was calculated as the number of
sialic acids per complex-type N-glycan, i.e., sum [(complex-
type species with n sialic acids)∗n]/sum(complex-type species).
Sialylation/Galactose represents the number of sialic acids per
galactose on complex-type species, i.e., sialylation divided by
galactosylation. High-mannose represents the fraction of high-
mannose type N-glycans, i.e., sum of all structures where
the core is elongated only by mannoses, while hybrid-type
glycans represent the structures that are either hybrid-type or
have only one antenna. In addition, for the O-glycosylation
on IgA1, glycosylation features were defined as follows.
#HexNAc represents the number of N-acetylhexosamines per O-
glycopeptide, i.e., sum [(species with nN-acetylhexosamines)∗n].
#Hex represents the number of hexoses per O-glycopeptide, i.e.,
sum [(species with n hexoses)∗n]. #SA represents the number of
sialic acids per O-glycopeptide, i.e., sum [(species with n sialic
acids)∗n]. Hex/HexNAc represents the number of hexoses per
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N-acetylhexosamine, i.e., #Hex divided by #HexNAc. Finally,
SA/Hex represents the number of sialic acids per hexose, i.e., #SA
divided by #Hex.
Statistical Analysis
From each duplicate pair of samples, the sample with the higher
absolute signal intensity per glycopeptide cluster was used for
statistical analyses (Supplemental Table S3). The IgG and IgA
glycosylation features in plasma and saliva originating from the
same donor were compared using the Wilcoxon signed rank
test (wilcox.test function from the MASS package) in R [v3.1.2;
R Foundation for Statistical Computing, Vienna, Austria (41)]
and RStudio (v0.98.1091; RStudio, Inc.; Supplemental Table S4).
Correlation analysis was performed between the saliva and
plasma samples using the cor.test function from the R stats
package (use = pairwise.complete.obs, method = spearman) to
obtain the correlation coefficient (rho) and associated p-value
(Table 1). TheWilcoxon signed rank test and correlation analysis
were only performed when data from at least 11 paired (plasma
and saliva from the same donor) samples were available, which
was the case for IgG1 N297, IgG2/3 N297, IgG4 N297, IgA2
N205, and IgA2 N47. Bonferroni correction was performed to
account for multiple testing, resulting in a p-value threshold for
significance of 0.05/28 = 0.00179. Graphs were created either in
Microsoft Excel 2010 or Graphpad Prism 7.
RESULTS
Paired plasma and saliva samples were collected from 19 healthy
donors. From these samples, IgG and IgA were separately
purified in duplicate using bead-based affinity chromatography.
Samples were trypsin-digested and analyzed by nanoLC-ESI-
QTOF-MS. Glycopeptides were identified on the basis of the
registered m/z, tandem mass spectrometric analyses as well
as literature information on immunoglobulin glycosylation
(Supplemental Table S1, Supplemental Figure S1, S3).
Glycosylation features were calculated for each glycosylation site
of IgG, IgA, JC, and SC (Supplemental Table S3).
IgG N-Glycosylation
For IgG1 and IgG2/3 N297, 27 different glycan compositions
each were quantified in both the plasma and saliva
samples, and 13 for IgG4 N297 (Supplemental Figure S3A,
Supplemental Table S1A). IgG1 and IgG4 derived from saliva
showed a slightly lower degree of galactosylation and sialylation
as compared to plasma (for example, 1.1 and 1.3 times lower
medians for IgG1 and IgG4 galactosylation, respectively). In
contrast, high-mannose and hybrid-type glycans were more
abundant in salivary IgG1 and IgG2/3, as compared to plasma
(for example, 2.7 and 3.4 times higher medians for IgG1 and
IgG2/3 high-mannose type glycans, respectively; Figure 2,
Supplemental Table S4). For IgG1 and IgG2/3, a significant
correlation was observed for the fucosylation, bisection,
sialylation and sialylation/galactose between plasma and saliva
(Table 1), showing the similarities in glycosylation features
between the two biofluids to be conserved across the different
donors. IgG4 showed similar behavior (Table 1).
IgA N-Glycosylation
For IgA2 N205 and N47, 15 and 10 different glycoforms were
quantified, respectively, in both the saliva and the plasma
samples (Supplemental Figure S3B, Supplemental Table S1B).
TheN-glycans were of the complex-type and mainly diantennary
(>98% of total abundance). Two to five-fold differences were
observed in the relative abundances of the different glycan
types present on plasma- vs. saliva-derived IgA2: salivary N-
glycans at both N205 and N47 showed a higher degree of
bisection and a lower degree of galactosylation, sialylation,
and sialylation/galactose (Figure 2, Supplemental Table S4).
None of the tested glycosylation traits on IgA2 showed a
significant correlation between plasma and saliva samples
(Table 1). Of note, for IgA2 N-glycosylation site N47 a truncated
glycopeptide, i.e., (W)SESGQN47VTAR(N), was registered. This
peptide features a tryptic C-terminal cleavage while the N-
terminus stems from a chymotryptic cleavage site. The predicted
tryptic peptide (K)VFPLSLDSTPQDNVVVACLVQGFFPEPLSV
TWSESGQN47VTAR(N) was not observed.
The glycopeptides with the peptide moieties LAGKPT
HVNVSVVMAEVDGTCY and LAGKPTHVNVSVVMAEVD
GTC (truncated; t) were assigned to both IgA1 and IgA2
covering the glycosylation sites N340 and N327, respectively,
as these peptide portions are common to both IgA subclasses
(Supplemental Table S2). The previously reported sequence
variant of IgA2 N327, MAGKPTHIN327VSVVMAEADGTC(Y),
was not observed in our samples, also not with the naturally
occurring polymorphisms I326V and A335V (17, 42, 43).
The absolute MS signals of the truncated variant were higher
in plasma samples, while those relating to the sequence
including the C-terminal tyrosine were higher in saliva
(Supplemental Table S3). Twenty-one and eight different
glycoforms could be quantified on the full-length and the
truncated sequence, respectively (Supplemental Table S1B).
Furthermore, trends of lower fucosylation (1.4 times lower),
galactosylation (2 times lower) and sialylation (5 times lower)
and higher bisection (1.7 times higher) in saliva as compared to
plasma were observed for IgA1/2 N340/327, but not for IgA1/2
N340/327t (Figure 2, Supplemental Table S4).
IgA1N144 and IgA2N131 share the same tryptic glycopeptide
sequence LSLHRPALEDLLLGSEAN144/131LTCTLTGLR.
While nearly all samples failed to provide data of sufficient
quality to derive a glycosylation profile, the three samples
which did pass data curation (one from plasma and two
from saliva, not paired) showed up to 20% high-mannose
type glycans and up to 3% hybrid-type/mono-antennary
glycans, in addition to the complex-type N-glycans (Figure 2).
In contrast to other IgA N-glycosylation sites, glycans at
N144/131 were almost entirely afucosylated (<1% fucosylation;
Supplemental Tables S3, S4).
For IgA2 N92, in all samples only non-glycosylated
peptides with the sequence HYTN92PSQDVTVPCPVPPPP
PCCHPR [allotype A2m(1)] were observed. Moreover, samples
treated with N-glycosidase F did not show deamidated forms
of this peptide, indicating that no glycosylated variants
of N92 were present prior to N-glycosidase F digestion
(Supplemental Table S2).
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TABLE 1 | Correlation of derived glycan traits between saliva and plasma samples as shown by the Spearman’s correlation coefficient (rho) and associated p-values.
Fucosylation Bisection Galactosylation Sialylation Sialic acid/galactose
Protein Site Peptide Npair rho p-value rho p-value rho p-value Rho p-value rho p-value
IgG1 N297 EEQYNSTYR 17 0.973 4.7E-06 0.877 < 1E-07 0.627 0.0084 0.843 9.7E-07 0.961 4.6E-07
IgG2/3 N297 EEQFNSTFR 17 0.716 0.0017 0.936 < 1E-07 0.699 0.0025 0.748 8.4E-04 0.885 < 1E-07
IgG4 N297 EEQFNSTYR 12 NA NA 0.965 < 1E-07 0.706 0.013 0.762 0.0059 0.434 0.16
IgA2 N205 TPLTANITK 16 0.232 0.39 0.474 0.066 −0.0529 0.85 0.191 0.48 0.232 0.39
IgA2 N47 SESGQNVTAR 13 NA NA 0.412 0.16 −0.242 0.43 0.181 0.55 0.423 0.15
The numbers of included pairs are listed under “Npair .” p-values significant after Bonferroni correction are shown in bold (α = 1.7910
−3 ). The correlation for IgA1/2 N144/131 and
N340/327, JC N71, the SC N-glycosylation and the IgA1 O-glycosylation was not assessed because this data was present in less than 11 paired samples (plasma and saliva from the
same individual).
FIGURE 2 | Glycosylation features for each of the glycosylation sites found in IgG, IgA, and the JC. The bar graphs represent the medians per glycosylation site (red
for plasma and blue for saliva) and the black dots represent the individual data points for each donor. A Wilcoxon signed rank test was performed between paired
samples from plasma and saliva when the total number of pairs was > 10 (Supplemental Table S4). Significant differences are denoted by ***, non-significant
differences are denoted by ns. IgA1-N340t is the C-terminally-truncated version of IgA1-N340 and JC-N71m is the miscleavage variant of JC-N71. IgA1-N144 also
represents IgA2-N131, and IgA1-N340 and -N340t also represent IgA2-N327 and -N327t.
IgA1 O-Glycosylation
The potential O-glycosylation sites located within the
IgA1 hinge region were part of one large tryptic peptide:
HYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPR.
Forty-two O-glycopeptides were quantified. The collective
glycan composition consisted of two to five hexoses, three
to six HexNAcs and zero to five N-acetylneuraminic
acids, likely distributed over three to six O-glycans
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(Supplemental Table S1B). Only a minor trend of lower
(1.4 times lower) salivary O-glycan sialylation was observed as
compared to plasma (Figure 2).
Joining Chain (JC) N-Glycosylation
The single N-glycosylation site N71 at the JC was observed
on two tryptic peptides: EN71ISDPTSPLR (JC N71) and
the miscleaved IIVPLNNREN71ISDPTSPLR (JC N71m). In
general, this glycosylation site contained a higher fraction
of monoantennary and hybrid-type glycans than the IgA
constant domain N-glycosylation sites (between 20 and 50%;
Supplemental Table S1C). Furthermore, for this site similar
differences between saliva and plasma were observed as for the
IgA1 and IgA2 heavy chainN-glycosylation sites, namely a higher
bisection (3.2 times higher) and lower galactosylation (1.1 times
lower) and sialylation (1.7 times lower) in the saliva-derived
samples (Figure 2, Supplemental Table S4). The miscleaved
glycopeptides showed a higher abundance of fucosylation as
compared to the expected tryptic glycopeptides (3.2 times higher
in plasma and 2.9 times higher in saliva; Figure 2).
Secretory Component (SC) N-Glycosylation
All seven N-glycosylation sites of the SC were detected after
tryptic digestion of salivary SIgA. Low-intensity signals of
SC glycopeptides were also seen in a few plasma samples
(Supplemental Table S3). N-glycans at N135, N186, N421, and
N469 were determined to be complex-type and diantennary,
furthermore the antennae were fully galactosylated and partially
sialylated (Supplemental Table S1D, Supplemental Figure S4).
In addition, on N499, mono-antennary species were identified.
The observed glycoforms carried zero to five fucoses, and tandem
mass spectrometry indicated the presence of both core and
antennary fucosylation (Figure 3, Supplemental Figure S1). On
N135, N469, and N499 between 1 and 4% bisection was observed
(Supplemental Figure S4). The glycosylation sites N83 and N90
were present on the same tryptic peptide, and the joint glycan
composition H10N8F2−8S0−3 indicated that the glycans at these
two sites were similar to those on other SC sites.
DISCUSSION
Here we present the first site-specific glycosylation analysis
of antibodies in human saliva. IgG and IgA were purified
from the plasma and saliva of 19 healthy individuals, and
analyzed by LC-MS(/MS). Similar to previous studies on human
serum and colostrum IgG or IgA glycosylation which used a
comparable analytical methodology (17, 34, 35, 39), we observed
glycopeptides covering the N-glycosylation sites of IgG1, 2/3
and 4 at N297, IgA1 at N340 and N144, IgA2 at N327, N205
and N131, and of the IgA-associated JC at N71, and the O-
glycosylation sites in the IgA1 hinge region. We report several
non-sialylated glycoforms on the JC that have not been described
previously. Moreover, in both plasma and saliva samples we
characterized the glycosylation at IgA2 N-glycosylation site
N47, which had not extensively been described in literature
(17, 39). Finally, we provide an overview of the N-glycans at
all 7 glycosylation sites of the SC in saliva including hitherto
unreported molecular species, such as glycoforms with four or
five fucoses.
The region surrounding IgA2 N92 is polymorphic and can
produce two types of tryptic peptides, HYTN92PSQDVTVPC
PVPPPPPCCHPR [allotype A2m(1)] and HYTN92SSQDVTVP
CR [allotype A2m(2)] (44). Since we detected the tryptic IgA2
peptide HYTN92PSQDVTVPCPVPPPPPCCHPR in saliva and
plasma samples from all individuals included in our study, we
conclude that all carry at least one allele of IgA2 allotype A2m(1).
This was expected, given that this allele has a frequency of 0.985
in the Caucasian population (44, 45). Allotype A2m(2) peptides
were not observed in our samples. Two previous studies reported
the NPS sequence on the A2m(1) allotype to be N-glycosylated
(16, 46), even though the proline following the N92 in A2m(1)
does not match the consensus sequence for N-glycosylation.
Here, however, we found that IgA2 N92 was not glycosylated in
either plasma or saliva, in accordance with a previous report on
colostrum SIgA (17). In future research also donors expressing
the A2m(2) allotype should be included to obtain a complete
characterization of IgA glycosylation.
In the current study, we did not detect the (glyco)peptides
covering IgA2 N327 when searching for the expected tryptic
peptide sequence obtained fromUniProt entry IGHA2_HUMAN
(P01877) or its naturally occurring variants. However, instead
of the methionine in position 319 on IgA2 (25), a leucine was
previously reported in allotype A2m(1) (42, 43), resulting in
identical peptide sequences for both IgA2 N327 and IgA1 N340.
Our observation that all individuals studied expressed IgA2
allotype A2m(1), made us conclude that the glycopeptides that
we detected with peptide sequences LAGKPTHVNVSVVMA
EVDGTCY and LAGKPTHVNVSVVMAEVDGTC [truncated
(35, 47)] represented a mixture of IgA1 N340 and IgA2 N327.
The two differentially cleaved peptide sequences covering N71
of the JC showed a large variation in their glycan fucosylation,
with the miscleaved variant having about 3 times higher
fucosylation than the expected peptide. This indicates that the
core fucose might interfere with tryptic cleavage at R69. Similar
differences in fucosylation were found previously (17).
Saliva collection has multiple advantages over the collection
of plasma, for example, it is painless and does not require special
instrumentation or trained personnel. Specialized devices for
saliva collection making use of swabs or chewing on paraffin
wax do exist (1, 20). However, we utilized the simplest method,
i.e., unassisted, unstimulated drooling, and found that this was
sufficient to obtain IgG and IgA for a thorough glycomic
analysis. A limitation of the current method might be that
only solubilized antibodies were obtained, while the fraction
associated to, for example, mucins was precipitated during
sample preparation. Furthermore, before saliva can be used
as a sample for diagnostics, further research is necessary to
evaluate robustness in terms of sample collection mode, time
point and sample storage. Finally, although the current method
can be performed in a 96-well plate format and has the potential
to be automated, for its application in a routine laboratory
or diagnostic setting further technological development is
required that allows the specific quantification of glycoforms of
interest, identified in the discovery phase. Despite the mentioned
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FIGURE 3 | Fragmentation spectrum of SC N469 H5N4F5S0. The parent ions were detected at m/z 1250.895 at a retention time of 13.1min and were assigned as
the triply charged variant of [M] = 3749.664 Da, representing SC N469 H5N4F5S0. The structure carries both core and antenna fucosylation, as the former proven by
[M+H]+ = 1746.942, representing the peptide sequence VPGN469VTAVLGETLK plus a GlcNAc and a fucose, and the latter by [M+H]
+ = 512.195 and 658.256,
representing the antenna oxonium ions with one or two fucoses, respectively. pep: VPGN469VTAVLGETLK, white circle: hexose, green circle: mannose, yellow circle:
galactose, blue square: N-acetylglucosamine, red triangle: fucose.
limitations, using saliva Ig glycosylation might have potential
in medical research in two different contexts: (i) as a proxy for
plasma Ig glycosylation reflecting systemic conditions, and (ii) as
a biomarker (panel) or therapeutic target for local perturbations
in the oral cavity.
Saliva Ig Glycosylation as Proxy For
Plasma Ig Glycosylation
The glycosylation of, in particular, IgG as the most abundant
Ig in plasma has been proposed as a biomarker for various
physiological and pathological states in multiple large-scale
studies (36, 48, 49). Similarly, IgA1 O-glycosylation associates
with IgA nephropathy, and IgA1 N- and O-glycosylation showed
to alter with pregnancy and rheumatoid arthritis (12, 35, 50).
The vast majority of salivary IgG is thought to originate from
plasma, and thus differences in glycosylation between plasma-
and saliva-derived IgG likely originate from theminority (<20%)
of locally produced IgG (20, 22). Here we found salivary
IgG at N297 to exhibit a slightly lower galactosylation and
sialylation, and a slightly higher abundance of high-mannose
and hybrid-type glycans as compared to plasma. However, most
IgG glycosylation features, except galactosylation, correlated well
between plasma and saliva. This indicates that these features have
potential as plasma IgG proxies and, thus, as biomarkers for
the systemic health status. Low galactosylation and sialylation
of plasma IgG are associated with inflammation and various
autoimmune diseases (51, 52). Additionally, galactosylation
and sialylation are known to influence the binding of IgG
to FcγRs and the C1q protein (7, 53). This suggests that
the slight IgG glycosylation differences we found between the
two biofluids from healthy individuals may arise from the
locally higher inflammatory state in the oral cavity, since
it is constantly exposed to pathogens. This aspect should
be taken into account when further exploring the use of
salivary IgG glycosylation as biomarker for systemic diseases,
with special attention regarding possible co-occurring oral
inflammatory conditions, such as periodontitis (gum disease).
In contrast to IgG, the N-glycosylation of IgA was not
correlated between plasma and saliva in our study. This
is likely due to either the different origin of plasma cells
producing the two pools of IgA proteins or to a difference in
processing, such as dimerization and J-chain binding, or their
translocation through the epithelial cell layer. Our findings in
healthy individuals aged between 20 and 42 years suggest that
salivary IgA cannot be used as a proxy for plasma IgA N-
glycosylation.
Saliva Ig Glycosylation as a Biomarker
(Panel) or Therapeutic Target for Local
Perturbations in the Oral Cavity
Differences of Ig glycosylation in locally produced biofluids
can be exploited as biomarkers for local pathological processes.
Accordingly, IgG glycosylation in cerebrospinal and synovial
fluid from multiple sclerosis and rheumatoid arthritis patients,
respectively, revealed biofluid-specific associations with disease
(14, 15). In addition, patients with advanced periodontitis
were reported to exhibit a lower salivary IgG galactosylation
than healthy individuals (18). Our data suggest that salivary
IgA N-glycosylation analysis also provides a promising tool
to detect local glycosylation perturbations in the oral cavity
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which might reflect pathological processes. IgA is the most
abundant antibody in human saliva, and SIgA is regarded
as an important first line of defense against pathogens on
mucosal surfaces (11, 20, 21). Interestingly, the N-glycosylation
profile reported for colostrum-derived SIgA (17) is similar to
our data on salivary SIgA, in terms of a high abundance of
glycoforms carrying a bisecting GlcNAc, contrary to plasma-
derived IgA. This suggests that in healthy individuals, SIgA
shares a common N-glycosylation profile, whether it originates
from the salivary or mammary glands, but differs from the
IgA glycosylation profile in circulation. This might be related
to the fact that both salivary and milk SIgA enter the
gastrointestinal tract via the same route, and can exert similar
functions while passing the oral cavity and the gastrointestinal
tract.
Salivary IgA and JC showed a considerably higher bisection
and lower galactosylation and sialylation at all observed sites
of N-glycosylation, except for the truncated variants of IgA1
N340 and IgA2 N327 lacking the C-terminal tyrosine, which had
a similar glycosylation profile in plasma and saliva. Moreover,
the truncated version was low-abundant in saliva and highly
abundant in plasma. Therefore we hypothesize that the truncated
form originates from circulation and is present in saliva due to
leakage or transport from circulation (22), while the full-length
variant might mainly be produced and secreted locally in the oral
cavity. The majority of salivary IgA and JC is produced locally
in plasma B cells of the glandular stroma (20, 26). This suggests
that changes in the glycosylation machinery of specifically these
cells are the cause for the substantial glycosylation differences
between plasma and saliva. For example, an upregulation of
beta-1,4-N-acetylglucosaminyltransferase III (GnT-III/MGAT3)
and a downregulation of beta-1,4-galactosyltransferase (B4GalT)
and beta-galactoside-alpha-2,6-sialyltransferase (St6Gal) 1 in the
glandular stroma B cells could be responsible for the observed
differences in IgA N-glycosylation. Alternatively, the pIgR-
enabled transport of IgA across the epithelium, the dimerization
of IgA, and the binding of the J-chain might be selective
for certain glycoforms of IgA. However, for the binding to
the pIgR this appears unlikely taking into account a previous
study which reported that the removal of either the N- or O-
glycans of polymeric IgA had no influence on pIgR-mediated
transcytosis (54). An additional explanation for the differences
between plasma and salivary IgA glycosylation might be the
presence of glycosidases from oral microbiota in saliva that
can alter the glycosylation after SIgA secretion (55). Finally,
it could be speculated that asialoglycoprotein receptors, which
are located primarily in the liver, could alter the overall
glycosylation of plasma IgA by specifically removing non-
sialylated proteins from circulation (56), thus leading to a
higher level of sialylation compared to saliva. However, this
would not explain the differences in the levels of bisection
between plasma and saliva. The functional consequences of
differences in IgA N-glycosylation are at this point not well
understood: The N-glycans on the constant region of IgA
do not seem to be essential for FcR binding, in contrast
to the ones on IgG (13). However, IgA sialylation has been
shown to be required for dectin-1-mediated transport of SIgA
across the epithelium of intestinal cells (11). Furthermore,
in addition to the Fab-binding sites, SIgA fucosylation and
sialylation enable the binding of the antibody to pathogenic
bacteria, acting as a decoy to prevent bacterial adhesion to
the epithelium and subsequent infection (57–59). Finally, the
C-terminal N-glycan sialic acids have recently been reported
to directly inhibit sialic acid-binding viruses like influenza
(60).
The fact that we did not find differences between salivary and
plasma IgA1 O-glycosylation, except for a slight trend of lower
sialylation in saliva, is likely due to their inherently different
biosynthetic pathways as compared to N-glycans, involving
distinct glycosyltransferases (61). Additionally, we here evaluated
allO-glycosylation sites simultaneously at the same glycopeptide,
which provides less resolution than analysis on the single-
structure level. Thus, it is difficult to judge on the usefulness of
IgA O-glycosylation as a potential diagnostic biomarker based
on our data. However, future investigations should further assess
IgA O-glycosylation in a specific disease context, since in plasma
it has been associated with pathologies, such as IgA nephropathy
and Sjögren’s syndrome (12, 62, 63).
A comparison of the salivary IgA SC with plasma was not
possible, due to insufficient signal intensities of the plasma SC
from most individuals in our study, most likely due to its low
abundance in plasma. N-glycans on the SC have been shown
to be crucial for various functional aspects of SIgA (59). For
example, SC glycosylation enables the innate protection against
mucosal pathogens (64). Furthermore, SC glycans are essential
for a correct localization of IgA in the mucosal lining, resulting
in protection from bacterial infection in the respiratory tract
of mice (65). Because of the important and diverse role of SC
glycosylation, future studies should examine whether salivary SC
glycosylation is associated with, for example, periodontitis, to
explore its potential as a diagnostic biomarker or therapeutic
target.
Conclusions
Large differences were found between the glycosylation of
plasma- and saliva-derived IgA and its JC, while this was
not the case for IgG. This suggests that SIgA, locally
produced by plasma B cells in the glandular stroma, differs in
glycosylation from IgA of the circulation, that presumably is
largely produced by circulating plasma cells, pointing toward
distinct regulatory mechanisms. An alternative explanation
is that SIgA dimerization or transport into the oral cavity
might be glycoform-specific, or that certain IgA-producing B
cells, expressing a specific glycosylation repertoire, may be
relocated to the glandular stroma after activation. The observed
differences between plasma and salivary IgA make biofluid-
specific analysis of SIgA glycosylation (including the JC and
SC) a promising tool for mucosal disease-related biomarker
research. IgG glycosylation, on the other hand, showed a good
correlation between plasma and saliva in healthy individuals,
indicating that salivary IgG might be a proxy to study plasma
IgG in situations where a healthy oral environment can be
assumed.
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